Press Release
`
`
`
`DR. REDDY'S LABORATORIES LTD.
`8-2-337, Road No. 3, Banjara Hills,
`Hyderabad - 500034. Telangana, India.
`
`
`
`CONTACT
`
`INVESTOR RELATIONS
`
`MEDIA RELATIONS
`
`SAUNAK SAVLA
`saunaks@drreddys.com
`(Ph: +91-40-49002135)
`
`CALVIN PRINTER
`calvinprinter@drreddys.com
`(Ph: +91-40- 49002121)
`
`
`………………………………………………………………………………………………………………………..……………….
`
`
`Dr. Reddy’s completes acquisition of product portfolio from TEVA
`
`Hyderabad, India, August 3, 2016 For Immediate Release
`…..….…………………………………………………………………………………………………………………………………………………………………...
`
`Hyderabad, India and Princeton, USA — Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE:
`DRREDDY, NYSE: RDY) today announced that it successfully completed the previously announced
`acquisition of eight Abbreviated New Drug Applications (ANDAs) in the U.S. from Teva Pharmaceutical
`Industries Ltd. (NYSE and TASE: TEVA) and an affiliate of Allergan plc (NYSE: AGN). The acquired
`portfolio consists of products that are being divested by Teva as a precondition to its closing of the
`acquisition of Allergan’s generics business.
`
`The portfolio being acquired is a mix of six ANDAs pending approval, one approved ANDA and one ANDA
`with tentative approval, and comprises complex generic products across diverse dosage forms. The
`combined sales of the branded versions of the products in the U.S. is approximately $3.5 billion MAT for
`the most recent twelve months ending in June 2016 according to IMS Health*. The products include
`Buprenorphine HCl/Naloxone HCl Sublingual Film (generic equivalent to Suboxone™ sublingual film),
`Ethinyl estradiol/Ethonogestrel Vaginal Ring (generic equivalent to NuvaRing™), Ezetimibe/Simvastatin
`Tablets (generic equivalent to Vytorin™), Metformin HCl/Saxagliptin ER Tablets (generic equivalent to
`Kombiglyze XR™), Tobramycin Inhalation Solution (generic equivalent to Tobi™), Phentermine
`HCl/Topiramate ER Capsules (generic equivalent to Qsymia™), Imiquimod Topical Cream (generic
`equivalent to Zyclara™ 3.75% Cream), and Ramelteon Tablets (generic equivalent to Rozerem™).
`
`
`*IMS National Sales Perspectives: Retail and Non-Retail MAT June 2016
`
`……………………………………………………………………………………..……………………………………………………………………………………………………………………..……………….
`About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
`committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &
`Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom
`pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
`cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major
`markets include – USA, Russia & CIS and India. For more information, log on to: www.drreddys.com
`……………………………………………………………………………………………………………………………………………………………………..
`Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the
`management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results,
`performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-
`looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts",
`"potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ
`materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
`credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and
`morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the
`policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
`
`The company assumes no obligation to update any information contained herein.
`
`
`
`
`
`DRL - EXHIBIT 1051
`DRL001